Physician profile
Jeremy S Taylor
NPI 1356605752
$270,697.80
in general payments reported to CMS, 2019-2025
59 companies · $93K in 2025
The $93K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,558 · 2021: $15K · 2022: $28K · 2023: $24K · 2024: $92K · 2025: $93K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $182K · Travel and Lodging: $19K · Food and Beverage: $8,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $182,450.89 |
| Travel and Lodging | $19,188.35 |
| Food and Beverage | $8,069.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $163,405.85 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $83,746.41 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $8,452.92 | 2019-2023 | Steglujan, Steglatro, Segluromet |
| Abbott Laboratories | $5,282.38 | 2019-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Amgen INC. | $1,039.71 | 2019-2025 | Tepezza, Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $888.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $861.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $780.22 | 2022-2025 | |
| Insulet Corporation | $699.27 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $671.19 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $580.60 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Dexcom, INC. | $499.49 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $468.00 | 2019-2025 | |
| Esperion Therapeutics, INC. | $364.75 | 2020-2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.51 | 2019-2023 | Cycloset |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $185.82 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Abbvie INC. | $185.29 | 2019-2025 | Ubrelvy |
| Pfizer INC. | $166.60 | 2019-2024 | |
| Recordati_rare_diseases_inc. | $156.77 | 2020-2024 | Isturisa, Signifor Lar |
| Lifescan, INC. | $154.85 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $148.43 | 2020-2024 | Unithroid |
| Becton, Dickinson and Company | $142.56 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $140.23 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $127.28 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Valeritas, INC. | $102.92 | 2019 | |
| Horizon Therapeutics Plc | $101.13 | 2022-2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $90.37 | 2022-2025 | Yorvipath |
| Ibsa Pharma INC. | $74.88 | 2020-2021 | |
| Astellas Pharma US INC | $53.47 | 2023-2025 | Veozah |
| Ultragenyx Pharmaceutical INC. | $50.02 | 2019-2020 | |
| Amarin Pharma, INC. | $47.66 | 2019 | |
| Amryt Pharma Holdings Ltd | $47.32 | 2023 | Mycapssa |
| Eusa Pharma (US) LLC | $45.48 | 2022 | |
| Antares Pharma, INC. | $42.46 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Kyowa Kirin, INC. | $42.40 | 2024 | Crysvita |
| Zealand Pharma US, INC. | $40.42 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $40.25 | 2020 | |
| Medtronic Minimed, INC. | $39.51 | 2020 | |
| Janssen Pharmaceuticals, INC | $38.91 | 2019-2020 | |
| Embecta Corp. | $38.52 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Arbor Pharmaceuticals, INC. | $36.30 | 2021 | |
| Acella Pharmaceuticals, LLC | $31.05 | 2024-2025 | NP Thyroid 60 |
| Tolmar, INC. | $29.77 | 2024 | |
| Cequr Corporation | $29.39 | 2024-2025 | Cequr Simplicity |
| Grt US Holding, INC. | $27.79 | 2021-2022 | |
| Shire North American Group INC | $26.01 | 2019 | |
| Halozyme INC | $23.69 | 2023 | |
| Nalpropion Pharmaceuticals LLC | $22.68 | 2019 | |
| Eisai INC. | $22.28 | 2019 | |
| Surmodics, INC. | $20.74 | 2022 | |
| Neurocrine Biosciences, INC. | $20.68 | 2025 | |
| Radius Health, INC. | $20.58 | 2023 | Tymlos |
| Rochester Medical Corporation | $19.66 | 2021 | |
| Beta Bionics, INC. | $19.39 | 2024 | Ilet Bionic Pancreas |
| Vifor Pharma, INC. | $17.38 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $17.06 | 2019 | |
| Nestle Healthcare Nutrition INC. | $16.37 | 2021 | |
| Currax Pharmaceuticals LLC | $15.35 | 2023 | Contrave, Nexlizet, Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $13.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.